NASDAQ (usa) | 6715.56 | -12.11 | -0.18% | |
FTSE 100 (london) | 7487.96 | -5.12 | -0.07% | |
DAX (german) | 13465.51 | 235.94 | 1.78% | |
NIKKEI 225 (japan) | 22420.08 | 408.47 | 1.86% | |
Hang - Seng (hong kong) | 28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) | 3391.61 | 17.53 | 0.52% | |
KOSPI (korea) | 2556.47 | 33.04 | 1.31% | |
All Ordinaries (australia) | 6005.30 | 28.90 | 0.48% | |
BOVESPA (brazil) | 74092.76 | -215.73 | -0.29% |
Collegium Pharmaceutical Inc (NASDAQ: COLL)
COLL Technical Analysis
5
As on 9th Jun 2023 COLL STOCK Price closed @ 21.76 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 18.02 & Strong Buy for SHORT-TERM with Stoploss of 18.92 we also expect STOCK to react on Following IMPORTANT LEVELS. |
COLLSTOCK Price
Open | 21.92 | Change | Price | % |
High | 21.92 | 1 Day | -0.18 | -0.82 |
Low | 21.49 | 1 Week | -0.31 | -1.40 |
Close | 21.76 | 1 Month | -1.42 | -6.13 |
Volume | 198500 | 1 Year | 3.01 | 16.05 |
52 Week High 29.88 | 52 Week Low 14.22 |
NASDAQ USA Most Active Stocks
TSLA | 244.40 | 4.06% |
TTOO | 0.07 | -12.50% |
SOFI | 8.18 | 0.74% |
FFIE | 0.33 | 6.45% |
PONO | 1.72 | 2.38% |
AMD | 124.92 | 3.20% |
IDEX | 0.06 | 0.00% |
NKLA | 0.70 | 14.75% |
AMZN | 123.43 | -0.66% |
AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
COLL Daily Charts |
COLL Intraday Charts |
Whats New @ Bazaartrend |
COLL Free Analysis |
|
COLL Important Levels Intraday
RESISTANCE | 22.59 |
RESISTANCE | 22.32 |
RESISTANCE | 22.16 |
RESISTANCE | 21.99 |
SUPPORT | 21.53 |
SUPPORT | 21.36 |
SUPPORT | 21.20 |
SUPPORT | 20.93 |
COLL Forecast May 2024
4th UP Forecast | 32.38 |
3rd UP Forecast | 28.97 |
2nd UP Forecast | 26.87 |
1st UP Forecast | 24.76 |
1st DOWN Forecast | 18.76 |
2nd DOWN Forecast | 16.65 |
3rd DOWN Forecast | 14.55 |
4th DOWN Forecast | 11.14 |
COLL Weekly Forecast
4th UP Forecast | 24.65 |
3rd UP Forecast | 23.72 |
2nd UP Forecast | 23.15 |
1st UP Forecast | 22.58 |
1st DOWN Forecast | 20.94 |
2nd DOWN Forecast | 20.37 |
3rd DOWN Forecast | 19.80 |
4th DOWN Forecast | 18.87 |
COLL Forecast2024
4th UP Forecast | 52.94 |
3rd UP Forecast | 42.94 |
2nd UP Forecast | 36.76 |
1st UP Forecast | 30.58 |
1st DOWN Forecast | 12.94 |
2nd DOWN Forecast | 6.76 |
3rd DOWN Forecast | 0.58 |
4th DOWN Forecast | -9.42 |
Collegium Pharmaceutical Inc ( NASDAQ USA Symbol : COLL )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
COLL Other Details
Segment | EQ | |
Market Capital | 717691648.00 | |
Sector | Healthcare | |
Industry | Drug Manufacturers-Specialty & Generic | |
Offical website | > echo $website ; ?> |
COLL Address
COLL Latest News
COLL Business Profile
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts. Address: 100 Technology Center Drive, Stoughton, MA, United States, 02072
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service